ArticleJournal of pediatric gastroenterology and nutrition2026
A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen-matched healthy controls.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen-matched healthy controls.Journal of pediatric gastroenterology and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe latest European Society of Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria for celiac disease (CD) diagnosis reduced the requirement for a small intestinal biopsy but still, for most of the cases a small intestinal biopsy is required for a safe diagnosis: hence the attempt to identify serum biomarkers that could replace, in most of these latter cases, the requirement of the biopsy (what is called a "liquid biopsy"). The aim of this study is to identify a set of serum biomarkers able to differentiate celiac patients from age and human leukocyte antigen (HLA)-matched healthy controls.
methodsRelative concentration of 92 inflammation-linked proteins was examined in the sera of 50 children with CD compared with 50 HLA DQ2/8 and age-matched healthy controls born in genetically at-risk families, using proximity extension immunoassay technology (Olink Proteomics®) with the ProSeek Multiplex Inflammation panel.
resultsThree different multivariate analysis (Univariate and multivariate distribution analysis, random forest classification and linear discriminant analysis) localized a cluster of seven molecules (CASP8, CXCL9, NT-3, SIRT2, STAMBP, ST1A1, and TNFSF14) with a remarkable diagnostic potential, able to differentiate around 90% (95% confidence interval [CI]; 0.7-0.99) of CD patients from controls.
conclusionPatients with CD, compared to age- and HLA-matched healthy controls, show in their sera an increased expression of inflammatory molecules, involved in NF-κB cytokine signaling, cell apoptosis, and crypt proliferation pathways. A set of seven of these proteins can differentiate cases from controls with an accuracy higher than 90%. The implementation of this approach in clinical setting could in future facilitate a noninvasive and individualized approach for CD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.